A study revealed that the induction of the TGF-β SMAD regulatory pathway in the lung adenocarcinoma cell line A549, the breast cancer cell line BT-474, and the pancreatic adenocarcinoma cell line PANC-1, resulted in the significant downregulation of the levels of AGR2 [79]. This evidence concerns the gene AGR2 and breast cancer.